Domchek, Susan M <br/><br/>
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.  [electronic resource] 

 -  Gynecologic oncology  Feb 2016 
 - 199-203 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2015.12.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Drug Resistance, Neoplasm<br/>Female<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Germ-Line Mutation<br/>Humans<br/>Middle Aged<br/>Organoplatinum Compounds--pharmacology<br/>Ovarian Neoplasms--drug therapy<br/>Phthalazines--adverse effects<br/>Piperazines--adverse effects<br/>Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use<br/>Prospective Studies